(NASDAQ: CLNN) Clene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.05%.
Clene's earnings in 2026 is -$33,513,000.On average, 7 Wall Street analysts forecast CLNN's earnings for 2026 to be -$23,278,242, with the lowest CLNN earnings forecast at -$27,675,257, and the highest CLNN earnings forecast at -$16,905,700. On average, 7 Wall Street analysts forecast CLNN's earnings for 2027 to be -$19,185,350, with the lowest CLNN earnings forecast at -$40,197,998, and the highest CLNN earnings forecast at -$4,964,372.
In 2028, CLNN is forecast to generate $27,553,863 in earnings, with the lowest earnings forecast at -$7,764,099 and the highest earnings forecast at $79,027,440.